Table 1.
Characteristics of 505 patients hospitalised with community-acquired pneumonia
| Characteristics | All patients ( n = 505) |
|---|---|
| Age in years (SD) |
63.4 (18.0) |
| Male sex (%) |
295 (58.4) |
| Comorbidities (%) |
|
| Chronic obstructive pulmonary disease |
98 (19.4) |
| Congestive heart failure |
68 (13.5) |
| Renal disease |
40 (7.9) |
| Diabetes mellitus |
77 (15.2) |
| Liver disease |
2 (0.4) |
| Pneumonia Severity Index class I-III (%) |
279 (55.2) |
| Pneumonia Severity Index class IV-V (%) |
226 (44.8) |
| Pathogens (%) |
|
|
Streptococcus pneumoniae |
124 (24.6) |
|
Coxiella burnetii |
28 (5.5) |
|
Haemophilus influenzae |
27 (5.3) |
|
Legionella pneumophila |
20 (4.0) |
|
Chlamydophila species |
16 (3.2) |
|
Mycoplasma pneumoniae |
9 (1.8) |
|
Staphylococcus aureus |
9 (1.8) |
| Only viral pathogen |
35 (6.9) |
| Other pathogen |
27 (5.3) |
| No pathogen identified |
210 (41.6) |
| Empirical antibiotic treatment (%) |
|
| Beta-lactam, penicillins (monotherapy) |
254 (50.3) |
| Other beta-lactam (monotherapy) |
86 (17.0) |
| Beta-lactam, penicillins + quinolone |
34 (6.7) |
| Beta-lactam, penicillins + macrolides |
33 (6.5) |
| Other beta-lactam + aminoglycoside |
20 (4.0) |
| Other beta-lactam + quinolone |
16 (3.2) |
| Quinolone (monotherapy) |
11 (2.2) |
| Macrolides, lincosamides and streptogramins (monotherapy) |
11 (2.2) |
| Beta-lactam, penicillin + aminoglycoside |
7 (1.4) |
| Other beta-lactam, penicillin + macrolides |
7 (1.4) |
| Sulfanomides and trimethoprim (monotherapy) |
6 (1.2) |
| Tetracyclines (monotherapy) |
6 (1.2) |
| Other |
14 (2.8) |
| Outcomes |
|
| Length of hospital stay (IQR) |
8.5 (6.0-13.0) |
| Intensive care unit admission (%) |
38 (7.5) |
| In-hospital mortality (%) |
24 (4.8) |
| 30-Day mortality (%) |
26 (5.1) |
| One-year mortality (%) | 73 (14.5) ⟂ |
Data are presented as number (%), mean (SD) or median (IQR).
Abbreviations: IQR interquartile range, SD standard deviation.
⟂7 patients were lost to follow-up.